BloatingNCT07902882
A Clinical Trial to Examine the Effects of Gut Health Supplements to Improve Gut and Digestive Health and Function
A study testing Intervention in people with Bloating and Digestive Discomfort, run by JS Health & Vitamins at 1 site in United States.
Trial summary
This is a double-blind, randomized, placebo-controlled trial evaluating the efficacy of JSHealth's Debloat \& Detox supplement, used alone or in combination with their Probiotics supplement, on gut and digestive health and function in 60 female participants aged 18-45 with self-reported bloating and digestive… Read more about this study
- Who is it for?
- Ages 18 to 45 years, women only
- Conditions the study is for
- Bloating, Digestive Discomfort, Irritable Bowel Syndrome (IBS)
- What is being tested?
- Intervention
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Feb 2026to 19 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- Women only
- No healthy volunteers
- Adult
Who may be able to join
- Female aged 18-45.
- Have self-reported issues with bloating and digestive discomfort at least three times per week for the last three months.
- Willing to complete a two-week washout period of all other vitamins and supplements prior to starting the trial.
- Willing to maintain their standard dietary pattern, activity level, body weight, and sleep schedule for the duration of the study.
- Be generally healthy and not live with any uncontrolled chronic disease.
- Resides in the United States.
Who cannot join
- Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Previous diagnosis of liver disease or elevated liver enzymes.
- Anyone who is currently undergoing or planning to undergo any gut or weight-related procedures in the next six weeks.
- Anyone with any known allergies or hypersensitivities to any of the study product ingredients.
- Anyone who has taken any prescription medications or supplements (e.g., probiotics) targeting the gut or any antibiotics in the past three months or who plans to take any for the duration of the trial.
- Women who are pregnant, breastfeeding, or trying to conceive.
Show all 12Show fewer
- Anyone unwilling to follow the study protocol.
- Anyone following any particular restrictive dietary regimen, such as a ketogenic diet or intermittent fasting.
- Anyone who has undergone any surgeries or invasive treatments in the past six months or who has any planned during the study period.
- Anyone with a history of severe digestive disorders including but not limited to Irritable Bowel Disease (IBD), ulcerative colitis (UC), Crohn's disease, stomach cancer, or gastrointestinal tract surgeries.
- Anyone who is currently enrolled in or planning to participate in another research study in the next six weeks.
- Anyone with a history of substance abuse.
Trial locations and contacts
1 site in 1 country.
About this study
This is a double-blind, randomized, placebo-controlled trial evaluating the efficacy of JSHealth's Debloat \& Detox supplement, used alone or in combination with their Probiotics supplement, on gut and digestive health and function in 60 female participants aged 18-45 with self-reported bloating and digestive discomfort.
Participants will be randomly assigned to either the intervention or placebo group for eight weeks. During the first four weeks, intervention participants will take the Debloat \& Detox supplement and placebo participants will take a corresponding placebo. During weeks five through eight, intervention participants will add the Probiotic supplement and placebo participants will add a probiotic placebo. Outcomes will be assessed via study-specific questionnaires and abdominal circumference measurements at Baseline, Day 1 (after first use), and at the end of Weeks 2, 4, 6, and 8.
- Conditions
- Bloating, Digestive Discomfort, Irritable Bowel Syndrome (IBS), Flatulence, Constipation, Gut Health
- Being tested
- Intervention, Placebo
- Medical subject headings
- Irritable Bowel Syndrome, Flatulence, Constipation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
InterventionDietary supplement
Participants take the JSHealth Debloat \& Detox supplement (two tablets once daily after the first meal) during Weeks 1-4, then add the JSHealth Probiotic supplement (one tablet once daily after the first meal) during Weeks 5-8.
PlaceboDietary supplement
Participants take a placebo matching the Debloat \& Detox supplement during Weeks 1-4, then add a placebo matching the Probiotic supplement during Weeks 5-8.
| Study group | Role | What they receive |
|---|---|---|
| Intervention Group | Experimental | Not described Receives: Dietary Supplement: Intervention |
| Placebo Group | Placebo comparator | Not described Receives: Dietary Supplement: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in digestive and gut health symptoms including reduced stomach bloating and fluid retention
Assessed via study-specific self-reported questionnaires measuring perceived reduction in stomach bloating and fluid retention
Measured: Baseline, Day 1 (after first use), Week 2, and Week 4
Change in relief from symptoms of IBS
Assessed via study-specific self-reported questionnaires measuring relief from IBS symptoms, flatulence, and digestive discomfort
Measured: Baseline, Day 1 (after first use), Week 2, and Week 4
Change in relief from symptoms of flatulence
Assessed via study-specific self-reported questionnaires measuring relief from IBS symptoms, flatulence, and digestive discomfort
Measured: Baseline, Day 1 (after first use), Week 2, and Week 4
Change in relief from symptoms of digestive discomfort
Assessed via study-specific self-reported questionnaires measuring relief from IBS symptoms, flatulence, and digestive discomfort
Measured: Baseline, Day 1 (after first use), Week 2, and Week 4
Time to symptom relief
Assessed via study-specific self-reported questionnaires measuring time to onset of digestive symptom relief
Measured: Baseline, Day 1 (after first use), Week 2, and Week 4
Change in abdominal circumference
At-home independent waist/abdominal circumference measurement using a provided tape measure
Measured: Baseline, Week 2, Week 4, Week 6, and Week 8
Secondary outcomes (3)
Change in bloating and IBS symptoms with combination supplementation
Assessed via study-specific self-reported questionnaires measuring noticeably less bloating and IBS symptoms when Debloat \& Detox is used in combination with the Probiotic supplement
Measured: Baseline, Week 6, and Week 8
Change in relief from constipation
Assessed via study-specific self-reported questionnaires measuring relief from constipation when using both supplements in combination
Measured: Baseline, Week 6, and Week 8
Change in overall gut and digestive function
Assessed via study-specific self-reported questionnaires measuring overall improvement in gut and digestive function with combination supplementation
Measured: Baseline, Week 6, and Week 8
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2026
- Study start1 Feb 2026
- Primary completion19 Apr 2026
- Study completion19 Apr 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for BloatingStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- JS Health & Vitamins
- Sponsor type
- Industry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07902882
- Sponsor's protocol ID
- #20464
- Status last verified
- Oct 2026
- First submitted
- 21 Oct 2026
- Last updated
- 29 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Examine the Effects of Gut Health Supplements to Improve Gut and Digestive Health and Function
- ClinicalTrials.gov ID
- NCT07902882
- Acronym / sponsor ID
- #20464
- Conditions
- Bloating, Digestive Discomfort, Irritable Bowel Syndrome (IBS), Flatulence, Constipation, Gut Health
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- JS Health & VitaminsIndustry (pharma, biotech, devices)
- Collaborators
- Citruslabs
- Study start
- 1 Feb 2026 (actual)
- Primary completion
- 19 Apr 2026 (actual)
- Study completion
- 19 Apr 2026 (actual)
- First posted
- 29 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a double-blind, randomized, placebo-controlled trial evaluating the efficacy of JSHealth's Debloat \& Detox supplement, used alone or in combination with their Probiotics supplement, on gut and digestive health and function in 60 female participants aged 18-45 with self-reported bloating and digestive discomfort.
Participants will be randomly assigned to either the intervention or placebo group for eight weeks. During the first four weeks, intervention participants will take the Debloat \& Detox supplement and placebo participants will take a corresponding placebo. During weeks five through eight, intervention participants will add the Probiotic supplement and placebo participants will add a probiotic placebo. Outcomes will be assessed via study-specific questionnaires and abdominal circumference measurements at Baseline, Day 1 (after first use), and at the end of Weeks 2, 4, 6, and 8.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Intervention Group | Experimental | Dietary Supplement: Intervention |
| Placebo Group | Placebo comparator | Dietary Supplement: Placebo |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Female aged 18-45.
- Have self-reported issues with bloating and digestive discomfort at least three times per week for the last three months.
- Willing to complete a two-week washout period of all other vitamins and supplements prior to starting the trial.
- Willing to maintain their standard dietary pattern, activity level, body weight, and sleep schedule for the duration of the study.
- Be generally healthy and not live with any uncontrolled chronic disease.
Key exclusion criteria (12 listed)
- Any pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders.
- Previous diagnosis of liver disease or elevated liver enzymes.
- Anyone who is currently undergoing or planning to undergo any gut or weight-related procedures in the next six weeks.
- Anyone with any known allergies or hypersensitivities to any of the study product ingredients.
- Anyone who has taken any prescription medications or supplements (e.g., probiotics) targeting the gut or any antibiotics in the past three months or who plans to take any for the duration of the trial.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| InterventionParticipants take the JSHealth Debloat \& Detox supplement (two tablets once daily after the first meal) during Weeks 1-4, then add the JSHealth Probiotic supplement (one tablet once daily after the first meal) during Weeks 5-8. | Dietary supplement | Intervention Group |
| PlaceboParticipants take a placebo matching the Debloat \& Detox supplement during Weeks 1-4, then add a placebo matching the Probiotic supplement during Weeks 5-8. | Dietary supplement | Placebo Group |
Primary outcome
Change in digestive and gut health symptoms including reduced stomach bloating and fluid retention
Time frame: Baseline, Day 1 (after first use), Week 2, and Week 4
Assessed via study-specific self-reported questionnaires measuring perceived reduction in stomach bloating and fluid retention
Change in relief from symptoms of IBS
Time frame: Baseline, Day 1 (after first use), Week 2, and Week 4
Assessed via study-specific self-reported questionnaires measuring relief from IBS symptoms, flatulence, and digestive discomfort
Change in relief from symptoms of flatulence
Time frame: Baseline, Day 1 (after first use), Week 2, and Week 4
Assessed via study-specific self-reported questionnaires measuring relief from IBS symptoms, flatulence, and digestive discomfort
Change in relief from symptoms of digestive discomfort
Time frame: Baseline, Day 1 (after first use), Week 2, and Week 4
Assessed via study-specific self-reported questionnaires measuring relief from IBS symptoms, flatulence, and digestive discomfort
Time to symptom relief
Time frame: Baseline, Day 1 (after first use), Week 2, and Week 4
Assessed via study-specific self-reported questionnaires measuring time to onset of digestive symptom relief
Change in abdominal circumference
Time frame: Baseline, Week 2, Week 4, Week 6, and Week 8
At-home independent waist/abdominal circumference measurement using a provided tape measure
3 secondary outcomes
Change in bloating and IBS symptoms with combination supplementation
Time frame: Baseline, Week 6, and Week 8
Change in relief from constipation
Time frame: Baseline, Week 6, and Week 8
Change in overall gut and digestive function
Time frame: Baseline, Week 6, and Week 8
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
Related trials for Bloating
Recruiting
Effects of a Prebiotic-Probiotic Combination on Constipation Symptoms and Quality of Life
Constipation, Abdominal Pain
Not yet recruitingPhase 3
Rifaximin Treatment in Bloating Predominant Functional Bowel Disorders
Bloating, Rifaximin
Recruiting
Effects of Wheat Flour Milling Method on Glycemic Response and Gastrointestinal Symptoms
Gastrointestinal Irritation, Nutrition, Healthy
Active, not recruiting
The Safety And Efficacy Of A Probiotic Intervention On Lactulose Hydrogen Breath Test-Positive Patients And Related Gastrointestinal Symptoms
Small Intestinal Bacterial Overgrowth, SIBO
Recruiting
A Clinical Trial to Investigate the Safety and Efficacy of Bloat on Postprandial Bloating and Its Effects Over Time in Healthy Women
Bloating, Gastrointestinal Symptoms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intervention in people with Bloating and Digestive Discomfort, run by JS Health & Vitamins at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in digestive and gut health symptoms including reduced stomach bloating and fluid retention (time frame: Baseline, Day 1 (after first use), Week 2, and Week 4). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.